This brand name is authorized in Cyprus.
The drug TRIOFAN contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
WPY40FTH8K - XYLOMETAZOLINE
|
|
Xylometazoline acts directly on α-adrenoreceptors but does not act on β-receptors. When used topically as a nasal decongestant, xylometazoline acts rapidly and provides long-lasting relief. Onset of action is within minutes, the decongestant effect being prolonged and lasting for up to 10 hours. |
|
2
|
UNII
740J2QX53R - CARBOCYSTEINE
|
|
Carbocisteine (5-carboxymethyl L-cysteine) has been shown in normal and bronchitic animal models to affect the nature and amount of mucus glycoprotein that is secreted by the respiratory tract. An increase in the acid:neutral glycoprotein ratio of the mucus and a transformation of serous cells to mucus cells is known to be the initial response to irritation and will normally be followed by hypersecretion. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| R01AB06 | Xylometazoline | R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AB Sympathomimetics, combinations excl. corticosteroids |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.